No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Synbio Tech Inc. operates as a biotechnology enterprise, primarily focusing on the development and production of probiotics and their various applications. The company also handles the marketing and distribution of several products in China, such as lactic acid bacteria (LAB) beverages, LAB powders formulated for human health, and specialized probiotic solutions for the agriculture, forestry, fishery, and animal husbandry sectors. Established on June 1, 2000, the firm maintains its principal office in Kaohsiung City, Taiwan.
www.synbiotech.comNo one on the platform currently holds 1295.TWO.
No tracked institution reports a position in 1295.TWO as of their last filing.
No one on the platform has traded 1295.TWO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 7.4% | 9.0% | — | — | — | |
| Rev. Growth % | 5.0% | 7.1% | ||||
| Profit Margin % | 16.9% | 15.8% | ||||
| Free Cash Flow Margin % | -53.9% | -10.3% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.3B | +21.6% | $6.27 | $6.27–$6.27 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 4 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-10 | $1.94 | $1.59 | -18.0% |
| 2026-05-11 | $1.69 | $0.39 | -76.9% |
| 2026-03-11 | $1.23 | $1.22 | -0.8% |
| 2025-11-10 | $1.91 | $0.92 | -51.8% |
| -1.55% |
| $2.0B |
| — |
| 6492.TWOSenhwa Biosciences, Inc. | $34.35 | +1.63% | $3.1B | — |
| 6610.TWOTWi Biotechnology, Inc. | $40.95 | +2.25% | $8.4B | — |
Source: Financial Modeling Prep · peers by sector/industry